New Drug Offers 'Functional Cure' For Dangerous Liver Virus
The experimental drug let patients stop therapy, and 20% kept the virus suppressed for at least six months, researchers reported.
8 Articles
8 Articles
New Drug Offers 'Functional Cure' For Dangerous Liver Virus
WASHINGTON (AP) – A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver virus, what's called a "functional cure," researchers reported Thursday.
Experimental Hepatitis B Drug May Offer ‘Functional Cure’ for Some Patients
WASHINGTON (AP) — A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver virus, what’s called a “functional cure,” researchers reported Thursday. In two international studies, about 1 in 5 patients given the experimental drug saw their virus reduced to levels low enough for the immune […]
In the field of infectious diseases, a new experimental molecule is attracting global interest. Researchers are announcing that innovative treatment for hepatitis B allows for lasting suppression of the virus in some patients after drug discontinuation. This phenomenon is described as "functional healing".The results of two international trials open up opportunities for ... Read more The article New therapeutic breakthrough against the dangerous…
GSK has reported results from two international phase III trials showing that its experimental drug bepirovirsen achieved functional cure rates for chronic hepatitis B of up to 26% in certain patient groups, compared to 0% with normal treatment.
GSK’s hepatitis B drug touts functional curative potential in double Phase III win
Analysts are heralding bepirovirsen as a potentially strong future growth driver for GSK and its infectious disease portfolio.The post GSK’s hepatitis B drug touts functional curative potential in double Phase III win appeared first on Clinical Trials Arena.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
